Description
Springer Erythrocytes as Drug Carriers in Medicine 1st Editon 2013 Softbound by Ulrich Sprandel, James L. Way
The sixth meeting on the use of resealed annealed red blood cells was held in Irsee, Germany by the International Society for the Use of Resealed Erythrocytes (ISURE) on July 25-28, 1996. Although earlier meetings focused on the technology toward develop ment of methods and standardization for efficient, consistent encapsulation, most of the present studies now are directed toward the application use of these carrier blood cells. Basic studies now have been directed toward exploration of commercial applications. In deed, clinical trials were initiated to evaluate the dose-response curves employing L asparagenase in human patients. Also, studies have shown the use of thrombolytic agent in erythrocyte carriers with the use of human red blood cells to provide a new conceptual ap proach in thrombolytic therapy to prevent thrombosis in individuals with higher risk fac tors. For example, with the use of carrier red blood cells, the thrombolytic agents will have a greater potential of acting on clot formation without systemic activation and thus lower the risk of hemorrhage, which is always prevalent in the thrombolytic therapy. 1. A Model for the Assessment of Human Recombinant Interleukin 2 (RIL2) Coated Erythrocytes as a Delivery System for Immunotherapy.- 2. Human Recombinant Interleukin 2 Binds to Mouse Red Blood Cells via the Erythropoietin Receptor.- 3. In Vivo Survival of Human Energy-Replete Carrier Erythrocytes.- 4. The Entrapment of Polyethylene Glycol-Conjugated Adenosine Deaminase (Pegademase) and Native Adenosine Deaminase in Human Carrier Erythrocytes.- 5. Use of Erythrocytes as a New Route of Administration of Fibrinolytic Agents. Preliminary Results.- 6. Synthesis, Characterization and Erythrocyte Encapsulation of an Azidothymidine Homodinucleotide.- 7. Erythrocyte-Based Targeted Release to Macrophages of an Azidothymidine Homodinucleotide Prevents Retroviral Infection.- 8. The Entrapment of Mannose-Terminated Glucocerebrosidase (Alglucerase) in Human Carrier Erythrocytes.- 9. Macrophage Protection by Nucleoside and Nucleotide Analogue Administration.- 10. Inhibition of Murine AIDS by Combination of AZT and DDCTP-Loaded Erythrocytes.- 11. Red Blood Cells as a Glucocorticoids Delivery System.- 12. Organophosphorus Antagonism by Resealed Erythrocytes Containing Recombinant Paraoxonase.- 13. Biotinylation of Erythrocytes Prepares to Allow to Circulation-Stable Immunoerythrocytes Capable of Recognizing the Antigen.- 14. Biochemical Properties of Alcohol Dehydrogenase and Glutamate Dehydrogenase Encapsulated into Human Erythrocytes by a Hypotonic-Dialysis Procedure.- 15. Influence of Chemical Modification on “in Vivo” and “in Vitro” Mouse Carrier Erythrocyte Survival and Recognition.- 16. Rat Carrier Erythrocytes Circulate and Arrive to Organs.- 17. Encapsulation of Alcohol Dehydrogenase and Acetaldehyde Dehydrogenase into Human Erythrocytes by an Electroporation Procedure.- 18. Pharmacokinetics of Doxorubicin in Patients with Lymphoproliferative Disorders after Infusion of Doxorubicin-Loaded Erythrocytes.- 19. Binding of Daunorubicin and Doxorubicin to Erythrocytes Treated with Glutaraldehyde.